The conversation is about seeking alternatives to finasteride for hair loss treatment due to concerns about sexual side effects, with pyrilutamide mentioned as a potential alternative.
The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.
A 57-year-old man shared his 6-month hair regrowth progress using RU58841, Minoxidil, microneedling, and Nizoral. He experienced significant improvement, with a smaller bald spot, thicker hair, and hairline regrowth.
Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.
The conversation is about seeking new research on hair loss treatments beyond the commonly known ones like Minoxidil and Finasteride. Additions to the list of treatments include topical caffeine, alfatradiol, fluridil, stemoxydine, and upcoming treatments like TDM-105795 and verteporfin.
A user started using RU58841 a month ago after using finasteride and minoxidil for nearly three years, hoping for hair regrowth at the temples. Other users suggest vitamin B supplements and microneedling to improve hair thickness, and one mentions the possibility of a hair transplant for the temples.
CBD in an emu and lanolin oil preparation showed a 100% increase in hair growth, but the effectiveness may partly come from the oils. Users discussed proper CBD dosage, preparation methods, and skepticism about the study's quality.
The conclusion of the conversation is that the user, BreadButterCoffee, did not have success with dutasteride for hair loss and found better results with a combination of finasteride, minoxidil, and microneedling. They recommend trying microneedling for those who have been on medication for years with minimal improvement.
_the_orange_box_'s experience using oral minoxidil, with discussion about finasteride and the potential side effects of both treatments. Other users shared their own experiences related to hair loss treatments.
Finasteride can cause sexual side effects in less than 2% of men, but these often disappear over time, even if the treatment continues. Some users report persistent side effects, while others experience no issues or only temporary ones.
A person in their 20s is struggling with hair loss, using treatments like minoxidil and finasteride. Suggestions include self-improvement, therapy, hair transplants, and focusing on acceptance and confidence.
The conversation discusses whether dutasteride might cause less depression than finasteride for hair loss treatment, with some users suggesting it could due to different mechanisms of action or molecular size, while others express skepticism or share personal experiences with these medications.
A user's concern with their hair thinning while using dutasteride and oral minoxidil, which was switched from finasteride and topical minoxidil after 13 months. The conversation includes advice surrounding potential results, specific treatments used, and side effects.
A user's hair regrowth journey involved a hair transplant and using RU58841, finasteride, and minoxidil, with side effects managed by other medications.
A user shared a 60-day progress update on hair regrowth using only 5% Minoxidil foam once daily. Others suggested adding finasteride to address the underlying cause of hair loss and maintain long-term results.
A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.
The user is asking if the Hims Tropical tropical fin and min treatment is working for hair regrowth. Some users believe it is working, while others do not see a difference. The cost of the treatment is $195 for a 5 month supply.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but PhaseIII trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
People have been using finasteride for 10 to 20+ years to maintain their hairline, with many reporting success and no significant side effects. Some users have combined finasteride with minoxidil for better results, and a few have switched to dutasteride or added hair transplants when finasteride was less effective.
The conversation is about the anticipated release date of phaseII results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
GT20029 showed significant hair growth and safety in phaseII trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
The conversation discusses the comparison of Pyrilutamide PhaseII US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.
Kintor Pharma completed a successful PhaseII clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
Kintor Pharma successfully dosed the first patient in a PhaseII trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
Chinese company gets green light for Pyrilutamide PhaseII trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
The conversation discusses the completion of a PhaseII trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phaseII trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to PhaseII trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.
Kintor Pharma completed enrolling subjects for a PhaseIII trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.